Navigation Links
CureFAKtor Pharmaceuticals Receives Orphan Drug Designation for Its Lead Compound CFAK-C4 for the Treatment of Pancreatic Cancer
Date:1/18/2011

BUFFALO, N.Y., Jan. 18, 2011 /PRNewswire/ -- CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer,  today announced that its lead compound, CFAK-C4 , which is in development for the treatment of pancreatic cancer, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA). Orphan status is given to drugs and biologics that are being developed to treat rare medical conditions, specifically those affecting fewer than 200,000 persons in the U.S.  

Orphan Drug Designation provides for a number of potential incentives related to CFAK-C4, including a seven-year period of marketing exclusivity, reduced regulatory fees, certain tax credits, and additional regulatory support for research and development initiatives.

"Receiving Orphan Drug Designation by the FDA is an important milestone for CureFAKtor, as well as for pancreatic cancer patients who have the lowest survival rate of any cancer and limited treatment options," said H. Shep Wild, President and Chief Executive Officer of CureFAKtor Pharmaceuticals. "CFAK-C4 is the first clinical candidate derived from our broad FAK technology platform and we look forward to progressing CFAK-C4 into human clinical trials."  

CureFAKtor Pharmaceuticals is planning a Phase I clinical study of CFAK-C4 in combination with gemcitabine chemotherapy, the current standard of care for pancreatic cancer, in 2012.  

CureFAKtor Pharmaceuticals was formed in 2008 based on fundamental discoveries of distinguished cancer researcher Dr. William Cance, Chair, Surgical Oncology, Surgeon-in-Chief Roswell Park Cancer Institute.  The Company, to date, has been funded primarily by grants from the National Institutes of Health (NIH).   CureFAKtor's proprietary FAK technology platform may represent a significant breakthrough in the treatment of most so
'/>"/>

SOURCE CureFAKtor Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
2. Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA
3. Cumberland Pharmaceuticals Receives FDA Approval for New Formulation of Acetadote
4. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
5. Reportlinker Adds Watson Pharmaceuticals Inc.: PharmaVitae Profile
6. Reportlinker Adds OTC Pharmaceuticals: Global Industry Almanac
7. ADVENTRX Pharmaceuticals Announces Closing of $22.5 Million Financing
8. Anadys Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
9. Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
10. Topaz Pharmaceuticals Names Dr. Mark Strobeck Chief Business Officer
11. Optimer Pharmaceuticals Announces Key Additions to Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year 2015 results on Thursday, January 22, 2015, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
(Date:12/19/2014)... 18, 2014   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... results from its pivotal field study of AT-001 ... in dogs with osteoarthritis.  In the study, dogs ... that were statistically significant compared to placebo (p<0.05) ...
(Date:12/17/2014)... and SAN DIEGO , Dec. 17, 2014 ... ; AEX: PHIA) and Volcano Corporation (NASDAQ: VOLC ... for cardiovascular applications, today announced that they have entered into ... commence a tender offer to acquire all of the issued ... or a total equity purchase price of USD 1 billion ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8
... Spanish drug companies face a number of obstacles ...  From regulatory (FDA) and GMP compliance, to distribution agreements ... areas that must be coordinated.  Those issues have just ... U.S. company VPCI have entered into a joint association. ...
... Sherpa Clinical Packaging, a privately held provider of ... cutting ceremony today to mark the opening of ... San Diego, CA.  Sherpa,s employees and invited guests ... adjacent to the Althea Technologies campus in Sorrento ...
Cached Medicine Technology:Spanish Drug Companies Have New Support Option for the U.S. Market 2Sherpa Clinical Packaging Completes New Production Facility 2
(Date:12/20/2014)... December 21, 2014 MissyDress, a distinguished ... all prom lovers. The business has drastically cut prices ... dresses to everyone until Jan. 30, 2015. Many of ... sweetheart dresses, V-neck dresses, lace dresses, and more. , ... not there every day. Whether A-line princess prom dresses ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 The print ... Post, with a distribution of approximately 160,000 copies and ... distributed nationally through a vast social media strategy and ... outlets. To explore the digital version of the campaign, ... exclusive interview with the ladies of CTV’s The ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 As ... move forward in U.S. courts, Bernstein Liebhard LLP ... suggests that children treated with the medication may ... to breast development and lactation. The study, which ... children and adolescents who began treatment with risperidone, ...
(Date:12/20/2014)... December 20, 2014 Xarelto bleeding ... suffered uncontrollable bleeding and other serious side effects ... District of Louisiana for coordinated pretrial proceedings, Wright &amp;amp; ... Litigation (JPML) issued an order Friday to transfer 21 ... in 22 federal courts to the Louisiana district court ...
(Date:12/19/2014)... It’s very easy to become overwhelmed with the holidays and ... wayside until Christmas and the New Year are over. However, ... burning desire to just escape it all and get away, ... with a no-fuss, affordable package. Montrose Days Inn will book ... ensure that all accommodations are met. Plus, everyone has a ...
Breaking Medicine News(10 mins):Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2
... stock was ... $3.81 per share, IRVINE, Calif., Feb. ... received a letter, dated February 4,2008, from The NASDAQ Stock Market, notifying ... price of the,Company,s common stock had been below the $1.00 minimum bid ...
... standard, invasive method , , TUESDAY, Feb. 5 (HealthDay News) -- ... spread may be better than traditional, invasive procedures. , Although ... Journal of the American Medical Association , needs to ... people with lung cancer or suspected lung cancer. , "Currently, ...
... - A Road Taken Together, NORTH ADAMS, ... groups across the globe will join the National,Patient ... Week,March 2-8. The theme of the week, Patient ... for safer health care through partnership,among providers, patients, ...
... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), ... announced today that it has signed a,definitive agreement ... Home,Health Care Affiliates, Inc. and certain of its ... subject to post-closing adjustments., The transaction will ...
... suggests that a minimally invasive approach may accurately determine ... study in the February 6 issue of JAMA. , ... death in the United States. Determining the stage of ... prognosis, according to background information in the article. ...
... - ... - Special Items Reduce Net Income by $17.9 ... ), a world leader in products and technologies to,treat advanced cardiovascular disease, ... million, or $0.27 per diluted,share, compared to net income of $20.7 million, ...
Cached Medicine News:Health News:IDM Pharma Receives Notification from NASDAQ Relating to Minimum Bid Price 2Health News:Less Invasive Way to Stage Lung Cancer Shows Promise 2Health News:Less Invasive Way to Stage Lung Cancer Shows Promise 3Health News:Patient Safety Awareness Week March 2 to March 8, 2008 2Health News:Gentiva(R) Health Services Agrees to Acquire Major Home Health Provider in CON State of Mississippi 2Health News:Gentiva(R) Health Services Agrees to Acquire Major Home Health Provider in CON State of Mississippi 3Health News:Gentiva(R) Health Services Agrees to Acquire Major Home Health Provider in CON State of Mississippi 4Health News:Less invasive methods may provide accurate means to determine lung cancer stage 2Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 2Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 3Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 4Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 5Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 6Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 7Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 8Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 9Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 10Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 11Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 12Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 13Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 14Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 15Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 16Health News:Edwards Lifesciences Reports Strong Fourth Quarter Sales 17
... This compact system provides an ... preparation in the laboratory, satellite lab ... proven HEMA-TEK staining method with wedge-smear ... delivers complete standardization in a safe ...
It is a cardio-pulmonary exercise testing device....
... has digitally-controlled drive system which eliminates ... can wear out. There are no ... and fewer drive belts - resulting ... It can carry weights up to ...
... systems feature our internationally-acclaimed algorithm that ... algorithm has a proven record for ... situations; and it's just one of ... recognized market leader in the stress ...
Medicine Products: